Ozempic (semaglutide) lowers blood sugar in type 2 diabetes through three simultaneous mechanisms: it stimulates your pancreas to release more insulin when blood sugar is high, it suppresses a hormone that tells your liver to dump extra glucose into your bloodstream, and it slows digestion so sugar from meals enters your blood more gradually. In clinical trials, patients taking a 1.0 mg weekly dose saw their HbA1c drop by 1.5% to 1.8% over 30 to 56 weeks, a meaningful improvement for most people with type 2 diabetes.
How It Triggers Insulin Release
Your gut naturally produces a hormone called GLP-1 after you eat. GLP-1 signals your pancreas to release insulin, but it breaks down within minutes. Ozempic is a synthetic version of GLP-1 that’s been engineered to last much longer in the body, which is why it only needs to be injected once a week.
The key feature of this insulin release is that it’s glucose-dependent. Your pancreas ramps up insulin production only when blood sugar is elevated. When blood sugar drops back to normal, the signal eases off. This built-in safety mechanism makes dangerous low blood sugar (hypoglycemia) far less likely compared to older diabetes medications that push insulin out regardless of what your blood sugar is doing.
Blocking the Liver’s Sugar Release
Insulin isn’t the only hormone involved in blood sugar control. Your pancreas also produces glucagon, which does the opposite of insulin: it tells your liver to release stored glucose into your bloodstream. In type 2 diabetes, glucagon levels are often inappropriately high, which means the liver keeps pushing out glucose even when blood sugar is already elevated.
Ozempic suppresses glucagon secretion by binding to GLP-1 receptors in the pancreas. With less glucagon circulating, the liver stops flooding the bloodstream with unnecessary glucose. This is especially helpful for controlling fasting blood sugar, the number you see first thing in the morning before eating anything.
Slowing Digestion to Prevent Spikes
After a meal, your blood sugar can spike rapidly as your stomach empties food into the small intestine, where carbohydrates are absorbed. Ozempic activates GLP-1 receptors on gastric neuronal cells, which slows the rate at which food leaves your stomach. The result is a more gradual release of glucose into the bloodstream rather than a sharp post-meal surge.
This slower gastric emptying also creates a lasting sense of fullness, which naturally reduces appetite and calorie intake. It’s one of the reasons Ozempic causes significant weight loss in many patients, a benefit that feeds back into better diabetes control (more on that below).
Weight Loss and Insulin Resistance
Type 2 diabetes is closely tied to insulin resistance, a state where your cells don’t respond well to insulin. Excess body fat, particularly around the abdomen, is a major driver of that resistance. Ozempic helps break this cycle by promoting weight loss through reduced appetite and slower digestion.
Research published in The Journal of Clinical Endocrinology & Metabolism found that improvements in insulin resistance on semaglutide were primarily driven by weight loss. But there was also an effect independent of weight: the drug’s suppression of glucagon and its direct lowering of fasting blood glucose contributed to better insulin sensitivity on their own. After 12 weeks, patients on semaglutide showed reduced fasting and post-meal glucagon levels compared to placebo. In practical terms, this means Ozempic improves how well your body uses insulin through multiple routes, not just by helping you lose weight.
Cardiovascular and Kidney Benefits
Heart disease is the leading cause of death in people with type 2 diabetes, so cardiovascular protection matters. In the SUSTAIN 6 trial, patients taking semaglutide had a 26% lower rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) over two years compared to placebo: 6.6% versus 8.9%. A broader meta-analysis of GLP-1 receptor agonist trials found a 12% overall reduction in these events across the drug class.
Kidney disease is another serious complication of diabetes, and semaglutide appears to slow its progression. The FLOW trial, published in The New England Journal of Medicine, showed a 24% lower risk of kidney disease worsening in patients taking semaglutide. Kidney function declined more slowly by about 1.16 ml per minute per year compared to placebo. The protective effects likely come from the drug reducing inflammation, oxidative stress, and scarring in kidney tissue, since GLP-1 receptors exist on kidney and immune cells. Notably, this kidney benefit held regardless of how much weight patients lost.
What the Dosing Looks Like
Ozempic is a once-weekly injection given under the skin of your abdomen, thigh, or upper arm. You can take it any time of day, with or without food, as long as you keep the same day each week. If you need to shift your injection day, the doses just need to be at least 48 hours apart.
The starting dose is 0.25 mg, which is not actually a therapeutic dose. It exists solely to let your body adjust to the medication and minimize side effects. From there, the dose gradually increases. The maximum FDA-approved dose for type 2 diabetes is 2 mg once weekly. This slow escalation is important because jumping to a higher dose too quickly tends to worsen nausea and other gastrointestinal symptoms.
Common Side Effects
Nausea is the most frequently reported side effect, affecting 15% to 23% of patients. It tends to be worst during the early weeks and after each dose increase, then gradually improves as the body adjusts. Vomiting, diarrhea, and constipation also occur but are less common. The slower gastric emptying that helps with blood sugar control is the same mechanism behind most of these digestive side effects.
Most people find the nausea manageable, especially with the gradual dose increases built into the prescribing schedule. Eating smaller meals, avoiding high-fat foods, and not lying down immediately after eating can help.
Who Should Not Take Ozempic
Ozempic carries a boxed warning related to thyroid tumors. In animal studies, semaglutide caused a type of thyroid cancer called medullary thyroid carcinoma. The drug is contraindicated if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. It’s also contraindicated for anyone who has had a serious allergic reaction to semaglutide or any of its inactive ingredients. Symptoms of such a reaction include swelling of the face, lips, or throat and difficulty breathing.